{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:40:10Z","timestamp":1790743210412,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.medcli.2018.10.039","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T21:07:56Z","timestamp":1547586476000},"page":"47-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical profile of women diagnosed with Fabry disease non receiving enzyme replacement therapy"],"prefix":"10.1016","volume":"153","author":[{"given":"Miguel \u00c1ngel","family":"Barba-Romero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Serena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Maria","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Valverde C.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Climent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Huertas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Torra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2018.10.039_bib0155","first-page":"30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.medcli.2018.10.039_bib0160","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2018.10.039_bib0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.medcli.2018.10.039_bib0170","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.medcli.2018.10.039_bib0175","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.12914","article-title":"Time delays in the diagnosis and treatment of Fabry disease","volume":"71","author":"Reisin","year":"2017","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.medcli.2018.10.039_bib0180","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1651-2227.2002.tb03120.x","article-title":"X-chromosome inactivation and human genetic disease","volume":"91","author":"Lyon","year":"2002","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.medcli.2018.10.039_bib0185","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with\u00a0Fabry\u00a0disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin Genet"},{"key":"10.1016\/j.medcli.2018.10.039_bib0190","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s10897-008-9179-7","article-title":"Disease rarity, carrier status, and gender: a triple disadvantage for women with Fabry disease","volume":"17","author":"Gibas","year":"2008","journal-title":"J Genet Couns"},{"key":"10.1016\/j.medcli.2018.10.039_bib0195","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2018.10.039_bib0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A \u2013 replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2018.10.039_bib0205","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural history of Fabry disease in females in the Fabry Outcome Survey","volume":"43","author":"Deegan","year":"2006","journal-title":"J Med Genet"},{"key":"10.1016\/j.medcli.2018.10.039_bib0210","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.clinph.2008.02.004","article-title":"Neuropathic symptoms and findings in women with Fabry disease","volume":"119","author":"Laaksonen","year":"2008","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.medcli.2018.10.039_bib0215","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/GIM.0b013e3181f6e676","article-title":"Therapeutic goals in the treatment of Fabry disease","volume":"12","author":"Mehta","year":"2010","journal-title":"Genet Med"},{"key":"10.1016\/j.medcli.2018.10.039_bib0220","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.medcli.2018.10.039_bib0225","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ymgme.2011.03.022","article-title":"Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS \u2013 the Fabry Outcome Survey","volume":"103","author":"Hughes","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.medcli.2018.10.039_bib0230","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.medcli.2011.02.024","article-title":"Consensus for the study and treatment of Fabry disease GETER Foundation","volume":"137","author":"Garc\u00eda de Lorenzo","year":"2011","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2018.10.039_bib0235","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","volume":"55","author":"Levey","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.medcli.2018.10.039_bib0240","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","article-title":"Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings","volume":"57","author":"Devereux","year":"1986","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.medcli.2018.10.039_bib0245","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jpain.2003.12.005","article-title":"Validation of the Brief Pain Inventory for chronic nonmalignant pain","volume":"5","author":"Tan","year":"2004","journal-title":"J Pain"},{"key":"10.1016\/j.medcli.2018.10.039_bib0250","first-page":"79","article-title":"[The Spanish version of EuroQol: a description and its applications European Quality of Life scale]","volume":"112Suppl","author":"Badia","year":"1999","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2018.10.039_bib0255","series-title":"The EuroQol Group's International Task Force on Self-Reported Health Measuring Self-Reported Population Health: an International Perspective Based on EQ-5D","year":"2004"},{"key":"10.1016\/j.medcli.2018.10.039_bib0260","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/jmedgenet-2011-100407","article-title":"Fabry International Prognostic Index: a predictive severity score for Anderson-Fabry disease","volume":"49","author":"Hughes","year":"2012","journal-title":"J Med Genet"},{"key":"10.1016\/j.medcli.2018.10.039_bib0265","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF03402156","article-title":"Fabry disease: twenty novel alpha-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes","volume":"8","author":"Germain","year":"2002","journal-title":"Mol Med"},{"key":"10.1016\/j.medcli.2018.10.039_bib0270","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/humu.9172","article-title":"Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female","volume":"22","author":"Rodr\u00edguez-Mar\u00ed","year":"2003","journal-title":"Hum Mutat"},{"key":"10.1016\/j.medcli.2018.10.039_bib0275","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.medcli.2018.10.039_bib0280","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1399-0004.2009.01345.x","article-title":"Does geographical location influence the phenotype of Fabry disease in women in Europe?","volume":"77","author":"Barba Romero","year":"2010","journal-title":"Clin Genet"},{"issue":"4 Suppl","key":"10.1016\/j.medcli.2018.10.039_bib0285","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jpeds.2009.07.003","article-title":"Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiences","volume":"155","author":"Martins","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.medcli.2018.10.039_bib0290","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ymgme.2014.11.005","article-title":"Absence of alpha-galactosidase cross-correctionin Fabry heterozygote cultured skin fibroblasts","volume":"114","author":"Fuller","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.medcli.2018.10.039_bib0295","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.medcli.2018.10.039_bib0300","doi-asserted-by":"crossref","unstructured":"Barba-Romero M-\u00c1, on behalf of The Spanish FOS Investigators G. Gender differences in the application of Spanish criteria for initiation of enzyme replacement therapy for Fabry disease in the Fabry Outcome Survey. Tikkanen R, ed. Int J Mol Sci. 2016;17(12):1965. https:\/\/doi.org\/10.3390\/ijms17121965.","DOI":"10.3390\/ijms17121965"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775318307486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775318307486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:50:05Z","timestamp":1758419405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775318307486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0025775318307486"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2018.10.039","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical profile of women diagnosed with Fabry disease non receiving enzyme replacement therapy","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2018.10.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}